After falling short of 2 billion won ($1.4 million) in annual revenue last year, Xcell Therapeutics is turning to Becton, Dickinson and Company’s (BD) lab equipment to reboot its commercial strategy.
BD’s FACSLyric Clinical Cell Analyzer (left) and FACS Melody Cell Sorter, which Xcell Therapeutics will distribute in Korea. (Courtesy of Xcell Therapeutics)
BD’s FACSLyric Clinical Cell Analyzer (left) and FACS Melody Cell Sorter, which Xcell Therapeutics will distribute in Korea. (Courtesy of Xcell Therapeutics)
The Kosdaq-listed cell culture media maker said Thursday that it has signed a distribution deal with BD, securing exclusive rights to sell the New Jersey-based medtech giant's flow cytometers, single-cell analysis systems, and research-use reagents in Korea starting in the second half of this year.
The company plans to bundle BD’s equipment with its own chemically defined media product, CellCor, targeting biotech labs, academic centers, and hospitals. Xcell said it expects BD-related sales to start showing up in its second-quarter earnings.
“This marks a major turning point in our revenue growth,” Xcell CEO Lee Ui-il said in a statement. “We’ve built the systems, the sales team, the marketing capability. Now we’re finally scaling.”
BD Korea Country General Manager Jason Hwang said the deal followed “thorough internal validation” of Xcell’s commercial infrastructure. No sales targets were disclosed.
Related articles
Becton Dickinson Korea completes merger with Bard Korea
Kim Ji-hye jkim404@docdocdoc.co.kr
See Other Articles
Copyright © KBR Unauthorized reproduction, redistribution prohibited